➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Medtronic
Harvard Business School
Moodys
Express Scripts

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 8,758,816

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,758,816
Title:Compositions comprising azelastine and methods of use thereof
Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also generally relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients, such as azelastine or pharmaceutically acceptable salts or esters thereof including azelastine hydrochloride, particularly wherein the compositions are provided in unit dosage form. In certain embodiments, the invention provides such unit dosage pharmaceutical compositions comprising azelastine hydrochloride formulated for use as nasal sprays and/or ocular solutions or drops. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of a variety of allergic and non-allergic conditions, particularly conjunctivitis, sinusitis, rhinitis and rhinosinusitis. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance.
Inventor(s): Fuge; Dennis (Somerset, NJ), Higson; John (Plymouth Meeting, PA), Roecklein; Bryan A. (Somerset, NJ), Balwani; Gul (West Windsor, NJ), D\'Addio; Alexander D. (Piscataway, NJ)
Assignee: Meda Pharmaceuticals Inc. (Somerset, NJ)
Application Number:12/569,548
Patent Claims:see list of patent claims

Details for Patent 8,758,816

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Hoffman-la Roche PEGASYS peginterferon alfa-2a VIAL; SUBCUTANEOUS 103964 001 2002-10-16   Start Trial Meda Pharmaceuticals Inc. (Somerset, NJ) 2024-11-24 RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a SYRINGE 103964 002 2002-10-16   Start Trial Meda Pharmaceuticals Inc. (Somerset, NJ) 2024-11-24 RX search
Glaxosmithkline Biologicals Sa FLUARIX QUADRIVALENT influenza virus vaccine SUSPENSION 125127 1 2020-07-02   Start Trial Meda Pharmaceuticals Inc. (Somerset, NJ) 2024-11-24 search
Id Biomedical Corporation Of Quebec FLULAVAL QUADRIVALENT influenza virus vaccine SUSPENSION 125163 1 2020-07-02   Start Trial Meda Pharmaceuticals Inc. (Somerset, NJ) 2024-11-24 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.